单位：[1]IQVIA, Shanghai, China,[2]AstraZeneca, Beijing, China,[3]IQVIA, Beijing, China,[4]China-Japan Friendship Hospital, Beijing, China,[5]The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,江苏省人民医院[6]China Pharmaceutical University, Nanjing, China,[7]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Qu S.,You X.,Liu T.,et al.COST-EFFECTIVENESS ANALYSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE SCREENING PROGRAM IN PRIMARY CARE FOR HIGH RISK PATIENTS IN CHINA[J].VALUE in HEALTH.2019,22:S353-S353.doi:10.1016/j.jval.2019.04.1725.
APA：
Qu, S.,You, X.,Liu, T.,Wang, L.,Yin, Z....&Zheng, J..(2019).COST-EFFECTIVENESS ANALYSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE SCREENING PROGRAM IN PRIMARY CARE FOR HIGH RISK PATIENTS IN CHINA.VALUE in HEALTH,22,
MLA：
Qu, S.,et al."COST-EFFECTIVENESS ANALYSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE SCREENING PROGRAM IN PRIMARY CARE FOR HIGH RISK PATIENTS IN CHINA".VALUE in HEALTH 22.(2019):S353-S353
